Sanofi hit by filing delays for key drugs, drops an early Sangamo thalassemia asset

Sanofi, in its third-quarter financials posted early Thursday morning, outlined a list of delays for a number of key assets as it dropped a biotech-partnered drug.

First up, those delays: We already knew its hemophilia hopeful fitusiran had problems after Sanofi started a new lower dose cohort in its phase 3 amid safety concerns, but now we know filing for the RNAi drug is not expected until 2024, after originally being penned in for next year.